Clinical trials: Esophagus SCC
Solid Tumor, Small Cell and Non-small Cell Lung Cancer
RAPA-201 Therapy of Solid Tumors
The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of…
- Conditions
- Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
- Trial name
- NCT05144698
- Testing
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Rapa Therapeutics LLC
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Surgical resection is currently the major treatment for esophageal carcinoma while disease progression still occurred in most cases within 3 years.
- Trial name
- NCT04390958
- Testing
- nab-paclitaxel, Cisplatin, Capecitabine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Chinese Academy of Medical Sciences
Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
At present, concurrent chemoradiotherapy (cCRT) with platin-based dual-drug regimen is the standard treatment for inoperable, locally advanced esophageal cancer in patients with a good performance status.
- Conditions
- Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy
- Trial name
- NCT06342167
- Testing
- Radiotherapy, Programmed Cell Death Protein 1 Inhibitor, Immunonutrition support
- Where
- 10 sites in China
- Volunteers
- 57 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ESCC
Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting
This is a prospective, single-arm, exploratory, single-center clinical study designed to evaluate the efficacy and safety of becotatug vedotin (MRG003) in combination with an investigator's choice of immune checkpoint inhibitor…
- Trial name
- VISTA-ESCC (NCT07892833)
- Testing
- Becotatug vedotin (MRG003)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Esophageal Cancer
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo…
- Trial name
- SKYSCRAPER-08 (NCT04540211)
- Testing
- Atezolizumab, Tiragolumab, Paclitaxel
- Where
- 67 sites in China, Hong Kong and 3 more
- Volunteers
- 461 people
- Sponsor
- Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
In this study, participants with histologically diagnosed locally advanced esophageal squamous cell carcinoma who have received preoperative cisplatin-based chemoradiotherapy followed by surgery harbouring high risk of tumor…
- Trial name
- NCT03322267
- Testing
- Pembrolizumab
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
Stage IV Esophagus Squamous Cell Carcinoma
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
To observe and evaluate the efficacy and safety of camrelizumab combined with chemotherapy or anlotinib in patients with advanced esophageal squamous cell carcinoma previously Treated With First-line Immunotherapy
- Trial name
- NCT05322499
- Testing
- Camrelizumab, Irinotecan, Paclitaxel
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Squamous Cell Carcinoma
Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy
Advanced esophageal squamous cell carcinoma patients who have failed first-line PD-1 inhibitor combined with chemotherapy lack a standard treatment option.
- Trial name
- NCT05990231
- Testing
- Cadonilimab combined Anlotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Esophageal Neoplasm, Esophageal Diseases
CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer
The objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with Itraconazole in patients with locally adcvanced esophageal squamous cancer
- Conditions
- Esophageal Neoplasm, Esophageal Diseases, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04481100
- Testing
- itraconazole
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Hangzhou Cancer Hospital
Esophageal Neoplasms
A Trial to Compare Preoperative Chemoradiation and Surgery Versus Surgery Alone in Squamous Cell Carcinoma of Oesophagus
Carcinoma of the esophagus is the among the most common cancers in Indian population. While adenocarcinoma is more common in western countries, in India squamous cell carcinoma is the more frequent form.
- Trial name
- NCT01151839
- Testing
- Esophagectomy, Neoadjuvant chemoradiation followed by surgery
- Where
- India
- Volunteers
- 100 people
- Sponsor
- All India Institute of Medical Sciences
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA
ARTemIS-Eso is a phase I-II, three-level, open-label trial with a dose-expansion cohort at recommended schedule in both esophageal cancer histological groups (squamous cell carcinoma and adenocarcinoma) of RCT and ImT…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Squamous Cell Carcinoma of the Esophagus
- Trial name
- ARTEMIS-Eso (NCT03307941)
- Testing
- Monalizumab, Oxaliplatin, 5-Fluorouracil
- Where
- Belgium
- Sponsor
- Jules Bordet Institute
Esophagus Squamous Cell Carcinoma (SCC), Metastatic Cancer
Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma
Esophageal or esophageal-gastric junction squamous cell cancer has dismal prognosis. And still no promising chemotherapeutic drugs is existed.
- Trial name
- DOSE (NCT03585673)
- Testing
- Docetaxel-PM, Oxaliplatin
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Sung Yong Oh
Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
This phase II trial studies how well pembrolizumab and palliative radiation therapy works in treating patients with esophagus, stomach, or gastroesophageal junction cancer that has spread to other parts of the body.
- Conditions
- Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach
- Trial name
- NCT02830594
- Testing
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Esophageal Cancer
Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection
This retrospective study is exploring the treatment effect and toxicity of adjuvant radiotherapy in patients diagnosed with esophageal squamous cell carcinoma after R0 resection.
- Trial name
- NCT05460403
- Testing
- Adjuvant Radiotherapy
- Where
- China
- Volunteers
- 3,591 people
- Sponsor
- Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
The study aimed to evaluate the efficacy and safety of sitravatinib in combination with tislelizumab as a second- or third-line treatment for participants with locally advanced, unresectable, or metastatic esophageal squamous…
- Trial name
- NCT05461794
- Testing
- Sitravatinib, Tislelizumab, Docetaxel
- Where
- 31 sites in China
- Volunteers
- 96 people
- Sponsor
- BeiGene
Esophageal Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002631
- Testing
- chemotherapy, cisplatin, fluorouracil
- Where
- 18 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Radiation Therapy Oncology Group
Esophageal Squamous Cell Carcinoma, Chemoradiation
Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC
This clinical trial has two stages: phase II and phase III. Eligible patients will be randomized 1:1 to the two arms: paclitaxel plus cisplatin and cisplatin plus 5-fluorouracil.
- Trial name
- NCT03623737
- Testing
- neoadjuvant chemoradiation
- Where
- Taiwan
- Volunteers
- 248 people
- Sponsor
- National Taiwan University Hospital
Time
Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell Carcinoma
The optimal interval between neoadjuvant chemradiotherapy and esophagectomy is still a question that needs to be explored for patients with esophageal squamous cell carcinoma.
- Trial name
- NCT06364566
- Testing
- Neoadjuvant chemradiotherapy, Minimally invasive esophagectomy
- Where
- China
- Volunteers
- 303 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Neoplasms
A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib
A study of second-line treatment of postoperative recurrence and metastasis of esophageal squamous cell carcinoma after chemotherapy with apatinib mesylate
- Trial name
- NCT03787251
- Testing
- Apatinib, The chemotherapeutic drug chosen by the investigator.
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
Multimodal treatment combining surgery with chemotherapy and/or radiotherapy is necessary to improve the chances of survival in patients with locally advanced thoracic esophageal cancer.
- Trial name
- HCHTOG1903 (NCT04138212)
- Testing
- Paclitaxel, Cisplatin, neoadjuvant chemoradiation therapy
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Henan Cancer Hospital